Instil Bio, Inc. TIL
We take great care to ensure that the data presented and summarized in this overview for Instil Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TIL
Top Purchases
Top Sells
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Insider Transactions at TIL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2022
|
R Kent Mc Gaughy Jr Director |
SELL
Other acquisition or disposition
|
Indirect |
260,323
-3.07%
|
-
|
|
Mar 23
2021
|
Bronson Crouch CEO and Chairman |
BUY
Open market or private purchase
|
Indirect |
450,000
+1.17%
|
$9,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
Bronson Crouch CEO and Chairman |
BUY
Conversion of derivative security
|
Indirect |
37,530,073
+22.71%
|
-
|
|
Mar 23
2021
|
R Kent Mc Gaughy Jr Director |
BUY
Open market or private purchase
|
Indirect |
450,000
+5.04%
|
$9,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
R Kent Mc Gaughy Jr Director |
BUY
Conversion of derivative security
|
Indirect |
8,028,790
+30.31%
|
-
|
|
Mar 23
2021
|
Jack Nielsen Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+2.35%
|
$6,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
Jack Nielsen Director |
BUY
Conversion of derivative security
|
Indirect |
12,186,787
+26.88%
|
-
|
|
Mar 23
2021
|
Nimish P Shah Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+24.0%
|
$6,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
Nimish P Shah Director |
BUY
Conversion of derivative security
|
Indirect |
6,565,076
+32.89%
|
-
|
|
Mar 23
2021
|
Vivo Capital Ix, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+2.35%
|
$6,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
Vivo Capital Ix, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
12,186,787
+26.88%
|
-
|
|
Mar 23
2021
|
Curative Ventures V LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
450,000
+1.17%
|
$9,000,000
$20.0 P/Share
|
|
Mar 23
2021
|
Curative Ventures V LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
37,530,073
+22.71%
|
-
|